Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Suzhou Abogen Biosciences Co., Ltd. is currently overseeing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners, ensuring that each case receives independent review. Both actions are situated within 1 distinct art unit, which suggests the company's current patent applications are focused on a specific sub-field of biotechnology. This concentration in 1 distinct art unit allows for a consistent technical context while still benefiting from the perspectives of 2 distinct examiners.
The busiest examiner, GROOMS, TIFFANY NICOLE, is handling 1 pending office action, which is 1 of the total 2 pending office actions. This distribution across 2 distinct examiners within a single art unit provides a balance of perspectives while maintaining a narrow technical focus. Practitioners should note that while the art unit is consistent, the 2 distinct examiners may apply different standards or interpretations to the 2 pending actions. This structure requires the legal team to manage 2 separate examiner relationships while navigating the specific rules of a single specialized unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PURDY, KYLE A | 1 | 41.0% | +35.7% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19104621 | COMPOSITION OF LIPID NANOPARTICLES | PURDY, KYLE A | — |
| 18697846 | One-Step Method for Synthesis of Circular RNA | GROOMS, TIFFANY NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19104621 | COMPOSITION OF LIPID NANOPARTICLES | PURDY, KYLE A | — |
| 18697846 | One-Step Method for Synthesis of Circular RNA | GROOMS, TIFFANY NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19104621 | COMPOSITION OF LIPID NANOPARTICLES | PURDY, KYLE A | 1611 | §102§103 | Non-Final OA | — | Pending | Feb 18, 2025 |
| 18697846 | One-Step Method for Synthesis of Circular RNA | GROOMS, TIFFANY NICOLE | 1637 | §102§103§112 | Non-Final OA | — | Pending | Apr 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuzhou Abogen Biosciences Co., Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kyle A Purdy has the most, with 1 of Suzhou Abogen Biosciences Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
